Day: February 4, 2022

Reports fourth quarter 2021 revenue of $11.9 million, GAAP diluted EPS of $0.31 and non-GAAP diluted EPS of $0.33 Announces full-year and first quarter 2022 financial guidanceWINTER SPRINGS, Fla., Feb. 04, 2022 (GLOBE NEWSWIRE) —  iRadimed Corporation (the “Company”) (NASDAQ: IRMD), a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only known provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures, today announced financial results for the three months and year ended December 31, 2021. “I am very happy to report these results. Fourth quarter revenue grew nearly 39% over the fourth quarter last year and was supported by record bookings that grew over 48% from the...

MONTREAL, Feb. 04, 2022 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (NASDAQ: PYR) (FRA: 8PY), a high-tech Company (hereinafter referred to as the “Company” or “PyroGenesis”), that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions to reduce greenhouse gases (“GHG”), today announced that the Company has been invited to present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Conference, which is being held virtually on February 8 – 11, 2022. Peter Pascali, CEO and Chair of PyroGenesis, is scheduled to present on Wednesday, February 9, 2022 at 1:30 PM Eastern Time. The webcast and replay of the Company’s presentation can be accessed at https://www.webcaster4.com/Webcast/Page/2840/44558 and on the investor relations section...

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days. About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs....

VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has completed enrollment in its Phase 2 NP-120 (“Ifenprodil”) idiopathic pulmonary fibrosis (“IPF’) and chronic cough study. The Company is projecting a data readout in calendar Q2, 2022. “We are very pleased to announce this update to the market on our IPF and chronic cough study and we look forward to having it completed and presenting the data,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals. Phase 2 IPF & Chronic Cough Study Summary The purpose of this proof-of-concept open label 20 patient Phase 2 human trial is to determine the efficacy of Ifenprodil in the preservation...

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today provides supplemental information on the ANAVEX®2-73 (blarcamesine) AVATAR Phase 3 trial for the treatment of adult patients with Rett syndrome. Following the successful completion of U.S. Phase 2 Rett syndrome study (ANAVEX®2-73-RS-001) as announced in December 2020, and the knowledge gained from it, the AVATAR study (ANAVEX®2-73-RS-002) appropriately updated endpoints according to ICH guidelines were approved by the U.K. Medicines and Healthcare...

BROOKFIELD, NEWS, Feb. 04, 2022 (GLOBE NEWSWIRE) — Brookfield Business Partners L.P. (NYSE: BBU) (TSX: BBU.UN) (“Brookfield Business Partners”) announced today financial results for the year ended December 31, 2021. “We had a successful 2021, generating strong financial performance and committing $2.2 billion of capital to acquire six new businesses,” said Cyrus Madon, CEO of Brookfield Business Partners. “Our focus is on onboarding our recent acquisitions and executing our business improvement plans. We are well positioned to continue building value and expect 2022 to be another active year for our business.”  Three Months EndedDecember 31,   Twelve Months EndedDecember 31,US$ millions (except per unit amounts), unaudited   2021     2020     2021   2020  Net income (loss) attributable to unitholders1 $ 41   $ 85   $ 643 $ (169 )Net...

Series  RIKS 26 0216 RIKS 37 0115Settlement Date  02/09/2022 02/09/2022Total Amount Allocated (MM)  5,855 5,085All Bids Awarded At (Price / Yield)  106.238 / -0.050 96.610 / 1.250Total Number of Bids Received  18 39Total Amount of All Bids Received (MM)  6,961 11,940Total Number of Successful Bids  12 13Number of Bids Allocated in Full  12 13Lowest Price / Highest Yield Allocated  106.238 / -0.050 96.610 / 1.250Highest Price / Lowest Yield Allocated  106.322 / -0.070 96.750 / 1.240Lowest Price / Highest Yield Allocated in Full  106.238 / -0.050 96.610 / 1.250Weighted Average of Successful Bids (Price/Yield)  106.270 / -0.058 96.658 / 1.247Best Bid (Price / Yield)  106.322 / -0.070 96.750 / 1.240Worst Bid (Price / Yield)  106.150 / -0.029 96.080 / 1.290Weighted Average of All Bids Received (Price...

4 February 2022, 12:00 CET Visiting the ArcelorMittal site in Dunkirk, France, today, French Prime Minister Jean Castex, Minister of Ecological Transition Barbara Pompili, and Minister of Industry Agnès Pannier-Runacher were welcomed by Eric Niedziela, Chairman of ArcelorMittal France and Vice President Climate Action ArcelorMittal Europe, Matthieu Jehl, CEO of ArcelorMittal France, Bruno Ribo, CEO of ArcelorMittal Méditerranée, and Yves Koeberlé, CEO of ArcelorMittal Europe – Flat Products. The Prime Minister announced support from the French Government for ArcelorMittal’s decarbonisation programme in France, which involves a €1.7 billion investment in its Fos-sur-Mer and Dunkirk sites in France. This investment will enable a profound transformation of steelmaking in France and a total reduction of close to 40% or 7.8 million tonnes per...

Municipality Finance PlcFinancial Statements Bulletin                                       4 February 2022 at 1:00 pm (EET) Municipality Finance Plc Financial Statements Bulletin 1 January–31 December 2021 In brief: MuniFin Group in 2021The Group’s net operating profit excluding unrealised fair value changes amounted EUR 213 million (EUR 197 million) and it increased by 8.0% (6.2%). The Group’s net interest income totalled EUR 280 million (EUR 254 million) and grew by 10.3% (5.8%). Costs in the financial year amounted to EUR 72 million (EUR 58 million). Costs excluding the non-recurring item grew as expected and were EUR 2.6 million higher, making the figure 4.4% greater than in the previous year. The net operating profit amounted to EUR 240 million (EUR 194 million). Unrealised fair value changes amounted to EUR 27 million (EUR -3...

To Nasdaq Copenhagen A/S                                4 February 2022                                        Announcement no. 13/2022 Jyske Realkredit to open 2.5% bond with 30-year interest only option and maturity in 2053 Jyske Realkredit will issue new covered bonds (særligt dækkede obligationer) from Capital Centre E. The bonds will be DKK-denominated fixed-rate callable bonds with a 2.5% coupon rate, 30-year interest only option and maturity on 1 October 2053. The bonds will be registered with VP SECURITIES A/S and Jyske Realkredit will apply for admission to trading of the bonds on NASDAQ Copenhagen A/S. The final terms will be published in a separate stock exchange announcement. Yours sincerelyJyske Realkredit www.jyskerealkredit.com